| Status | In progress |
| Technology type | Medicine |
| Decision | Selected |
| Reason for decision | Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in use addressed, and help them make the best use of NHS resources |
| Process | STA Standard |
| ID number | 6334 |
Provisional Schedule
| Expected publication | 28 January 2025 |
Project Team
| Project lead | Louise Jafferally |
Email enquiries
- If you have any queries please email TATeam4@nice.org.uk
| External Assessment Group | BMJ Technology Assessment Group (BMJ-TAG), BMJ |
Stakeholders
| Companies sponsors | Takeda UK (brentuximab vedotin) |
| Others | Department of Health and Social Care |
| NHS England | |
| Patient carer groups | Lymphoma Action |
| Professional groups | Association of Cancer Physicians |
| Cancer Research UK | |
| Royal College of Physicians | |
| Royal College of Radiologists | |
| Associated public health groups | None |
| Comparator companies | Accord Healthcare Limited (doxorubicin) (confidentiality agreement not signed, not participating) |
| Hospira (vinblastine) (confidentiality agreement not signed, not participating) | |
| Janssen-Cilag Ltd (doxorubicin) (confidentiality agreement not signed, not participating) | |
| Kyowa Kirin Ltd (bleomycin) (confidentiality agreement not signed, not participating) | |
| Medac GmbH (dacarbazine, doxorubicin) (confidentiality agreement not signed, not participating) | |
| Pfizer Limited (doxorubicin) (confidentiality agreement not signed, not participating) | |
| Seacross Pharmaceuticals Ltd (doxorubicin) (confidentiality agreement not signed, not participating) | |
| Teva Pharma B.V. (doxorubicin) (confidentiality agreement not signed, not participating) | |
| General commentators | All Wales Therapeutics and Toxicology Centre |
| British National Formulary | |
| Department of Health, Social Services and Public Safety for Northern Ireland | |
| Healthcare Improvement Scotland | |
| Medicines and Healthcare products Regulatory Agency | |
| Scottish Medicines Consortium | |
| Welsh Government | |
| Welsh Health Specialised Services Committee | |
| Relevant research groups | Institute of Cancer Research |
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 05 November 2024 | Committee meeting |
| 05 November 2024 | Declaration of interests |
| 05 July 2024 | Following a regulatory update from the company, the Committee meeting will now take place on 5 November 2024. |
| 02 February 2024 | Invitation to participate |
| 29 November 2023 - 09 January 2024 | Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators |
| 29 November 2023 | In progress. Appraisal in progress. |
| 06 October 2023 | For information, please see draft timelines. This evaluation is expected to start during late November 2023 with a consultation on the draft scope. It is then anticipated that the final scope will be released along with an invitation to participate in the evaluation during early-February 2024. Please note this evaluation will include a review of TA594 which originally published in August 2019. |
| 11 September 2023 | Awaiting development. Status change linked to Topic Selection Decision being set to Selected |
| 11 September 2023 | Topic selection |
| 22 August 2023 | This evaluation will include a review of TA594 published August 2019 |
| 20 July 2023 | Awaiting development. Status change linked to Topic Selection Decision being set to Selected |
For further information on our processes and methods, please see our CHTE processes and methods manual